Lv51
936 积分 2024-10-24 加入
Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD
29天前
已完结
Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients
1个月前
已完结
Selected biologic markers of inflammation and activity of Crohn's disease
3个月前
已完结
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
3个月前
已完结
Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody
3个月前
已完结
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
4个月前
已完结
Adverse events in IBD: to stop or continue immune suppressant and biologic treatment
5个月前
已完结
Adverse events in IBD: to stop or continue immune suppressant and biologic treatment
5个月前
已关闭
Biologic agents for IBD: practical insights
5个月前
已完结
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice
8个月前
已完结
皖公网安备34019202002308
